Medical Journals

Development of a Diva Subunit Vaccine Against Actinobacillus Pleuropneumoniae Infection.

Authors:
  • Maas Alexander
  • Meens Jochen
  • Baltes Nina
  • Hennig-Pauka Isabel
  • Gerlach Gerald-F

From: Institute for Microbiology, Department of Infectious Diseases, University of Veterinary Medicine Hannover, Foundation, 30173 Hannover, Germany.

Vaccine

  • Publish Date: Nov 2006
  • ISSN: 0264-410X
  • Volume: 24
  • Issue: 49-50
  • Pages: 7226-37
  • Medium: Print
  • Language: English
  • Citation (JAMA): Maas Alexander, Meens Jochen, Baltes Nina, et al. Development of a Diva Subunit Vaccine Against Actinobacillus Pleuropneumoniae Infection.. Vaccine Nov 2006;24:7226-37

Abstract

Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia which leads to high economic losses in the swine industry worldwide. Vaccination against this pathogen is hampered by the occurrence of 15 serotypes, and commonly used whole cell bacterin vaccines are not sufficiently cross-serotype protective. In addition, for generating and maintaining specified pathogen-free herds it is desirable to use DIVA (differentiating infected from vaccinated animals) vaccines. Based on a detergent wash extraction of outer membrane associated proteins and secreted proteins we developed a DIVA vaccine using the immunogenic ApxII toxin which is present in 13 of the 15 A. pleuropneumoniae serotypes as the DIVA antigen. The apxIIA gene was deleted in one strain each of serotypes 1, 2, and 5 using a single-step transconjugation system, and equal parts of detergent washes from these strains served as the vaccine antigen. After intramuscular immunisation all pigs developed a strong humoral immune response to the vaccine antigen and showed no reactivity in an ApxIIA ELISA. Upon challenge all pigs were completely protected from clinical symptoms in trials with a homologous (serotype 2) as well as with a heterologous strain (serotype 9); in addition, colonisation of the challenge strain was clearly reduced but not abolished completely. As a result of the highly efficient protection, however, immunised pigs did not develop antibodies to the DIVA-antigen at levels detectable by ELISA but only by a more sensitive Western blotting approach, thereby demonstrating the challenge in developing appropriate marker vaccines for the livestock industry.

Mesh Headings (Keywords): Actinobacillus Infections, Actinobacillus pleuropneumoniae, Animals, Antibody Formation, Bacterial Outer Membrane Proteins, Bacterial Vaccines, Blotting, Western, DNA, Bacterial, Enzyme-Linked Immunosorbent Assay, Mutation, Plasmids, Pleuropneumonia, Swine, Swine Diseases, Vaccination, Vaccines, Subunit


Check for Full Text / PubMed Unique Identifier (PMID): 17027123


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.